Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

NCT02171741 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BIBW 2992
DRUG: Docetaxel

Sponsor

Boehringer Ingelheim